CytoDyn Inc (OTCMKTS:CYDY) continues to move farther away from its 52-week low.
CYDY is currently trading at 2.21 up .04 gaining 1.84%. More than 1.32 million shares traded hands for the session, almost one-third its 30-day average volume of 3.29 million. The stock opened at $2.21and moved within a range of $2.06-$2.26.
CytoDyn Promotes Antonio Migliarese to CFO
- Chief Financial Officer (CFO) Antonio Migliarese has contributed immensely to the “late-stage biotechnology company” success
- Former CFO Michael Mulholland is stepped down citing personal reasons. He will however continue in the position of advisor to the CytoDyn
- Migliarese is a CPA and has graduated in Accounting from Oregon State University.
Earlier this week, CytoDynannounced to submit the results of its newly completed topline report of its CD12 Phase 3 clinical trial data for severe to critically ill COVID-19 patients to various regulatory agencies, including but not limited to agencies in India and the Philippines.
Migliaresecommented “I look forward to contributing to the CytoDyn executive team and continuing to create, drive and execute on the vision of CytoDyn’s financial organization, ensuring the Company is properly equipped for its next phase of growth and success in doing so. I am even more excited Michael has gratefully chosen to continue to serve and provide us with his wealth of knowledge and experience.”
|SHARES OUTSTANDING||612.88 M|
|SHARE FLOAT (%)||550.66 M (89.85%)|
|% HELD BY INSTITUTIONS||0.13|
Recent Stock Performance
|+/- EMA(20)||2.51 (-12.35%)|
|+/- SMA(50)||2.78 (-20.86%)|
|+/- SMA(200)||3.61 (-39.06%)|
|CCI20||-101.5026||Sell||Chaikin Money Flow||-0.1265||Sell|
|MACD||-0.4114||Sell||Money Flow Index||28.8764||Sell|
|STOCH (14,3)||29.4118||Buy||STOCH RSI||0.7202||Neutral|